newsfilter
← Latest News
GlobeNewswire·

Nutriband Signs Agreement With Brand Institute to Develop the Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch

NTRBNTRBW
  • Nutriband Inc. has signed an agreement with Brand Institute, Inc. to develop the worldwide commercial brand name & visual identity for its lead product, an abuse deterrent fentanyl transdermal system.
  • The product, currently designated AVERSA™ FENTANYL, utilizes Nutriband's AVERSA™ abuse deterrent transdermal technology to deter abuse, misuse, & accidental exposure.
  • Brand Institute holds a 75% global share of drug name approvals & was responsible for 87% of FDA-approved names in 2024, including many opioid chronic pain & abuse deterrent products.
  • Drug Safety Institute, a regulatory subsidiary of Brand Institute led by former officials from the FDA, EMA, Health Canada, USAN, & WHO, will provide regulatory services for the project.
  • Nutriband's AVERSA™ technology is protected by a broad international intellectual property portfolio with patents issued in 46 countries, including the US, Europe, Japan, & China.
  • The initiative aims to ensure the new brand name is distinct from sound-alike or look-alike names to prevent medication errors while maintaining drug accessibility for patients who need it.
  • Nutriband Inc. trades on NASDAQ under the symbols NTRB & NTRBW, with the project executed through its 4P Therapeutics subsidiary.